Immunic to Join March Conferences to Present Research

Immunic, Inc., a biotechnology firm focused on treating chronic inflammatory and autoimmune diseases, announced its participation in key scientific and investor conferences this March. The company will present at the 34th Annual Meeting of the Society for Virology in Hamburg, Germany, from March 4-7. Two abstracts have been selected for presentations, focusing on advancements in antiviral therapies.

Notably, Friedrich Hahn, Ph.D., from Friedrich-Alexander-Universität, will present research on dual host-targeting molecules. Alexandra Herrmann, Ph.D., from Immunic, will discuss novel DHODH inhibitors. Immunic will also participate in the Leerink Partners Global Healthcare Conference in Miami from March 10-12. CEO Daniel Vitt will engage in discussions on the firm's progress.